Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-Label, Dose-Finding, and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of JZP341 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT05631327 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT05631327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05631327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-Label, Dose-Finding, and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of JZP341 in Adult Participants With Advanced or Metastatic Solid Tumors
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
December 19, 2022
Completion date
April 24, 2024
Enrollment
12 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic solid tumor